HOME >> BIOLOGY >> NEWS
Zengen, Inc. receives patent application approval for proprietary peptide technology

WOODLAND HILLS, Calif. (October 2, 2003) - Zengen, Inc. announced today that the United States Patent Office has approved a patent application for "A Lys-Pro-Val Dimer, Formulations and Applications," which covers novel peptide CZEN 002. This marks the first patent application approval for CZEN 002, with issuance of the patent expected by the end of the year. In addition, Zengen holds multiple patents and patents-pending worldwide on its peptide technologies.

"This development provides further validation of the efficacy of CZEN 002," said R. Steven Davidson, Ph.D., President and CEO of Zengen. "The approved patent application claims are directed to the novel peptide, which has the ability to control infection and/or inflammation associated with, among other disease states, urogenital conditions, including vaginitis."

Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Company's proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. Zengen's peptides have broad applications as anti-inflammatory and anti-infective prescription pharmaceuticals and are based on the larger melanocortin peptide, alpha-Melanocyte-Stimulating Hormone (a-MSH).

About CZEN 002

A synthetic octapeptide, CZEN 002 was developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). There is abundant evidence of the anti-inflammatory and anti-infective activity of CZEN 002 from both in vivo and in vitro research.

Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth and subsequent interference with cell metabolism, all of which give rise to a broad range of life-threatening diseases and disorders. In preclinical and clinical studies, CZEN 002 has been shown to directly kill pathologi
'"/>

Contact: Kumiko Hakushi
hakushik@ruderfinn.com
310-479-9929
Zengen
2-Oct-2003


Page: 1 2

Related biology news :

1. Zengen, Inc. announces novel approach to reduce organ rejection
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
5. Research on carbohydrate metabolism receives historical recognition
6. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
7. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
8. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
9. University of Pittsburgh receives $10 million grant for head and neck cancer
10. LSU Vet School receives $9.9 million for infectious disease research
11. UCSB professor and director receives two national awards

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... and PETACH TIKVAH, Israel , April 20, ... developer of adult stem cell technologies for neurodegenerative diseases, announced ... present at the Alliance for Regenerative Medicine,s (ARM) 5 th ... April 27, 2017 at 09:40 EDT in Boston ... , MD, MHSc, Chief Medical Officer & Chief Operating Officer, ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... Labs . The move comes after the company changed focus to making analytical ... new brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, ...
(Date:4/19/2017)... Oregon and PUNE, India , April 19, 2017 ... "Membrane Microfiltration Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the ... garner $12,858 million by 2022, registering a CAGR of 9.6% from 2016 to ... ... ...
(Date:4/18/2017)... ... April 18, 2017 , ... METTLER TOLEDO ... to concentration levels and vice-versa. , One of the key applications for the ... concentration control or monitoring. The principle of this analytical method is based on ...
Breaking Biology Technology:
Cached News: